Emestedastat

Emestedastat (brand name Xanamem) is Actinogen Medical's oral pill that blocks an enzyme called 11β-HSD1, which regenerates active cortisol - the stress hormone - inside cells, including in the brain. The lead program is XanaMIA (NCT06125951), a 247-patient Phase 2b/3 study in early Alzheimer's that finished enrolling in December 2025 and has guided to a topline readout in November 2026. A separate Phase 2 in major depression with cognitive impairment (XanaCIDD) read out in 2024 and missed its primary cognitive endpoint, and an earlier Phase 2 in mild Alzheimer's (XanADu, 2019) also missed. That puts heavy weight on XanaMIA to keep the company viable [1][2][3].

Emestedastat is a first-in-class investigational compound - no 11β-HSD1 inhibitor has ever been approved for any indication. It carries no FDA breakthrough, fast track, orphan, or RMAT designations. The active lead trial, XanaMIA (NCT06125951), is registered as Phase 2 on ClinicalTrials.gov and described by Actinogen as Phase 2b/3, with enrollment of 247 completed in December 2025 and status now active, not recruiting [1][6]. Actinogen's most recent guidance is a topline readout in November 2026; timelines have slipped before, so confirm against the latest ASX disclosure rather than rely on a fixed quarter [7]. There is no FDA NDA pending; Actinogen is an Australia-based microcap (ASX:ACW) running on a single asset across two indications. Regulatory pathway: the XanaMIA trial is multinational with US sites, and the company has positioned it as a Phase 2b/3 study intended to support FDA approval as the primary regulator, with TGA approval to follow. The earlier XanaCIDD Phase 2 in major depression with cognitive symptoms (NCT05657691, n=167) completed in 2024 and missed its primary endpoint on the Cogstate Attention Composite, though Actinogen pointed to positive secondary signals in depression scores [2][8]. The XanADu Phase 2 in mild Alzheimer's (NCT02727699, n=185) also failed its primary cognitive endpoint back in 2019 [3].

Cortisol is the body's main stress hormone. Chronically high cortisol is toxic to the hippocampus, the brain region you need to form new memories - this is why people under prolonged stress develop memory problems and why Cushing's patients show cognitive decline. The enzyme 11β-HSD1 sits inside cells and converts inactive cortisone into active cortisol locally, including inside neurons. So even if your blood cortisol is normal, your brain can be making extra cortisol in the wrong places [4]. Emestedastat blocks 11β-HSD1 in the brain, turning down that local cortisol production. The bet: lowering brain cortisol slows the cognitive damage of Alzheimer's. There is some Alzheimer's-specific rationale beyond general cortisol toxicity - post-mortem studies have reported elevated 11β-HSD1 expression in AD brain tissue, and AD patients show HPA axis dysregulation (blunted diurnal cortisol rhythm) that correlates with hippocampal atrophy [4]. The honest summary: the AD-specific case is suggestive rather than load-bearing, and could equally describe other neurodegenerative diseases. No drug hitting this target has shown clinical cognitive benefit. Merck and Pfizer both ran 11β-HSD1 inhibitor programs for metabolic indications (type 2 diabetes) and both discontinued - efficacy on metabolic endpoints was modest and no neuro candidate from a major pharma has produced a positive Phase 2 in dementia. The XanaCIDD miss in depression weakens, not strengthens, the cognitive case.

XanaMIA (NCT06125951) is a randomized, placebo-controlled Phase 2b/3 trial of 10 mg once-daily emestedastat versus placebo in 247 patients with biomarker-confirmed early symptomatic Alzheimer's. The primary endpoint is the Clinical Dementia Rating - Sum of Boxes (CDR-SB) - a standard scale where clinicians rate memory, judgment, and daily function across six domains - measured over roughly 36 weeks of treatment [1][6]. Key secondary endpoints include a seven-point cognitive composite and the Amsterdam Activities of Daily Living scale. This is a meaningful upgrade from prior Actinogen trials, which used Cogstate Attention Composite and similar instruments that FDA has been cool to; CDR-SB is the same primary endpoint used in lecanemab and donanemab key trials and is well-accepted by regulators. The trial requires a positive plasma pTau biomarker for entry (Actinogen has used pTau181 as the enrichment marker, distinct from the pTau217 used by some competitor programs) - pTau is a blood marker that flags whether a patient's brain has Alzheimer's-specific pathology rather than mixed dementia. This is the same enrichment strategy that helped lecanemab and donanemab read out positive. The dose was selected from a Phase 1 dose-ranging study in healthy elderly (NCT04983368, n=107) that suggested 10 mg gave the best PD signal - pharmacodynamic shorthand for a biological readout showing the drug is actually engaging its target [5]. The concerns: 247 patients is small for an Alzheimer's CDR-SB readout (lecanemab's key was n≈1,800), and there is no active comparator. Enrollment is complete and the trial is active, not recruiting, so execution risk is now mostly on data analysis and unblinding rather than recruitment pace.

The model gives this drug a 4% chance of eventually being approved. That starts from the historical approval rate for Phase 2 drugs in this area - about 24% - then adjusts based on ten facts about the trial and its sponsor. The estimate is pulled down mainly by heavier-than-usual blinding, the sponsor's thin approval record, few secondary endpoints, and weak earlier-phase results. The remaining factors are close to average for this stage, so they don't shift the number much.

Efficacy risk is the dominant problem. The exact molecule already missed its primary endpoint in two prior Phase 2 trials - XanADu in mild Alzheimer's [3] and XanaCIDD in MDD with cognitive impairment [2]. The XanaMIA bet is that pTau enrichment plus the switch to CDR-SB will rescue a mechanism that hasn't shown a clean cognitive win yet. Regulatory risk on the endpoint itself is now lower than for prior Actinogen trials - CDR-SB is FDA-familiar - but n=247 is small and FDA has historically required a confirmatory study even on positive CDR-SB reads in this size range. Safety risk is moderate but not headline. 11β-HSD1 inhibition can theoretically blunt the cortisol stress response and impair glucose handling; earlier metabolic-program inhibitors were dropped for efficacy reasons rather than safety, but long-term cortisol modulation in elderly patients hasn't been characterized at scale. Execution and capital risk: Actinogen reported AU$23m in cash at December 2024 with annual burn of AU$8.7m, then raised AU$16.8m in February 2026, taking pro forma cash to ~AU$29.5m. Per the company, this extends runway beyond the November 2026 XanaMIA readout, so an emergency raise before unblinding is less likely than the prior version of this assessment implied [7]. A confirmatory Phase 3 would still require fresh capital. Commercial risk: even with a positive Phase 2b/3, the drug would face lecanemab and donanemab as established disease-modifying options with biomarker-confirmed efficacy on CDR-SB. A symptomatic cognitive benefit over 36 weeks would need to be large to carve out share against IV anti-amyloid antibodies.

Watch but don't anchor on it. This is binary microcap biotech - Actinogen lives or dies on the XanaMIA readout expected November 2026. The setup that would make this a real signal is straightforward: a statistically significant CDR-SB benefit consistent with the secondary cognitive composite, in the pTau-positive population. Anything less - a numeric trend, a subgroup-only result, a functional-but-not-cognitive miss - is not enough given the two prior failures of the same molecule. The capital picture is better than typical for a microcap heading into a binary readout: the Feb 2026 raise took pro forma cash to ~AU$29.5m, which the company has said funds operations through the readout [7]. That removes the dilution-before-readout overhang but does not change the binary nature of the outcome. If XanaMIA misses, the entire 11β-HSD1 cortisol-lowering hypothesis for Alzheimer's is effectively dead for the rest of the decade - no one else has a late-stage program in this mechanism for cognition. Check back when Actinogen pre-announces a readout window, and again on topline. Skip the company updates in between.